CREATE Medicines develops in vivo immune programming platforms using proprietary RNA-Chimeric Antigen Receptor (RNA-CAR) technology. Their approach directly engineers immune cells within the patient to target diseased cells, aiming to create scalable, off-the-shelf immunotherapies for oncology, autoimmunity, and fibrosis.
Funding
Funding not disclosed
Founders
Product
Problem
Developing effective immunotherapies for complex diseases like cancer, autoimmunity, and fibrosis often requires ex vivo cell manipulation, which can be time-consuming, costly, and limit scalability. Existing approaches struggle to achieve broad patient access and timely treatment initiation due to these logistical challenges.
Solution
CREATE Medicines is pioneering an in vivo immune programming platform utilizing proprietary RNA-Chimeric Antigen Receptor (RNA-CAR) technology. This platform enables direct programming of immune cells, including T cells, NK cells, and myeloid cells, within the patient's body. By delivering mRNA-lipid nanoparticle (LNP) constructs, CREATE Medicines engineers these cells to target and eliminate diseased cells, while also stimulating a broader immune response. This approach aims to create scalable, off-the-shelf immunotherapies that can be administered rapidly and repeatedly, potentially transforming treatment paradigms for a range of indications.
Target Audience
CREATE Medicines targets pharmaceutical and biotechnology companies seeking to advance novel immunotherapies for oncology, autoimmunity, and fibrosis, as well as clinical researchers and healthcare providers involved in treating these conditions.
Features
- Proprietary RNA-LNP CAR platform for in vivo immune cell programming.
- Capability to program multiple immune cell lineages: T cells, NK cells, and myeloid cells.
- First-in-human clinical data demonstrating in vivo CAR uptake, expression, and tolerable repeat dosing.
- Retrotransposon-mediated RNA engineering for potentially stable CAR expression.
- Targeted delivery via cell-specific receptors and LNPs for precise immune cell activation.
- Rapid concept-to-clinic timelines (<12 months) with low-cost manufacturing potential.
- Pipeline includes candidates targeting HER2, TROP2, and GPC3 for solid tumors, as well as CAR-T for B-cell depletion.
- Clinical validation through extensive datasets from over 40 patients, showing proof-of-mechanism, safety, and preliminary efficacy.